Advertisement
UK markets closed

  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     

  • FTSE 250

    20,286.03
    -45.77 (-0.23%)
     

  • AIM

    764.38
    -0.09 (-0.01%)
     

  • GBP/EUR

    1.1796
    -0.0009 (-0.07%)
     

  • GBP/USD

    1.2648
    +0.0006 (+0.05%)
     

  • Bitcoin GBP

    48,013.34
    -949.12 (-1.94%)
     

  • CMC Crypto 200

    1,268.07
    -15.76 (-1.23%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • DOW

    39,118.86
    -45.20 (-0.12%)
     

  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     

  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

  • HANG SENG

    17,718.61
    +2.14 (+0.01%)
     

  • DAX

    18,235.45
    +24.90 (+0.14%)
     

  • CAC 40

    7,479.40
    -51.32 (-0.68%)
     
Property :

8 UK holiday home businesses you could buy now

A holiday let could be a very sound investment, providing a decent income, capital growth and — somewhere to escape

China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment

Reuters
·1-min read
FILE PHOTO: An AstraZeneca logo is pictured in Brussels

(Reuters) - China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company said on Wednesday.

AstraZeneca said the approval by China's National Medical Products Administration (NMPA) was based on trials which showed that patients given the combination treatment lived without the disease getting worse longer than those given just Tagrisso.

The median progression-free survival of patients treated with Tagrisso and chemotherapy was 25.5 months, 8.8 months more than those treated with just Tagrisso.

(Reporting by Chandini Monnappa in Bengaluru; Editing by Savio D'Souza)